Abstract: Described herein are compositions and methods that are used to increase the expression of SCN2A, which may be used to treat neurological or psychiatric disorders. Antisense oligonucleotides that target upstream open reading frames (uORFs) may be administered to prevent translation initiation from a uORF to increase expression from a primary ORF (pORF), thus increasing the levels of SCN2A protein.
Type:
Grant
Filed:
January 17, 2019
Date of Patent:
August 1, 2023
Assignee:
The Florey Institute of Neuroscience and Mental Health
Abstract: The present disclosure relates generally to compounds having activity as voltage-gated sodium channel blockers and their use in the field of therapeutic treatment, including the therapy or management of conditions associated with excessive, unwanted, inadequate or otherwise undesirable sodium ion passage through cellular membranes via voltage-gated sodium channels. In some embodiments, the disclosure relates to aryloxy-substituted amines for use as sodium channel blockers or modulators. Methods for their manufacture and compositions containing the compounds are also disclosed.
Type:
Grant
Filed:
March 24, 2016
Date of Patent:
March 3, 2020
Assignees:
The Florey Institute, The University of Melbourne
Abstract: The present invention relates generally to a method of modulating glutathione metabolism in the central nervous system of mammals and to agents for use therein. More particularly, the present invention relates to a method of up-regulating glutathione metabolism in the central nervous system by up-regulating levels of glutathione precursor molecules. The method of the present invention is particularly useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by aberrant, unwanted or otherwise inappropriate central nervous system oxidation homeostasis including, but not limited to, schizophrenia.
Type:
Application
Filed:
February 23, 2018
Publication date:
June 28, 2018
Applicant:
The Florey Institute of Neuroscience & Mental Health
Inventors:
Ashley I. Bush, David L. Copolov, Michael Berk
Abstract: The present disclosure relates generally, but not exclusively, to compounds and their use in therapy, to compositions and agents comprising said compounds, to methods of treatment using said compounds, and their use in the manufacture of medicaments. The disclosure further relates to inhibitors of IRAP and their use in the treatment or prevention of Alzheimer's disease and the treatment and prevention of memory and cognitive disorders.
Type:
Application
Filed:
May 6, 2016
Publication date:
June 21, 2018
Applicants:
Monash University, The Florey Institute of Neuroscience and Mental Health, St. Vincent's Institute of Medical Research
Inventors:
Siew Yeen CHAI, Philip THOMPSON, Simon MOUNTFORD, Michael W. PARKER